STOCK TITAN
  1. Home
  2. News
  3. ARVN

Arvinas Inc - ARVN STOCK NEWS

Welcome to our dedicated news page for Arvinas (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arvinas's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arvinas's position in the market.

News
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
Rhea-AI Summary
Arvinas, Inc. (ARVN) to discuss vepdegestrant (ARV-471) data presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) and plans to expand the vepdegestrant development program in a conference call and webcast with Pfizer Inc. (PFE).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
30.77%
Tags
conferences
-
News
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
Rhea-AI Summary
Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) announced clinical data for vepdegestrant (ARV-471), a novel oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib (IBRANCE®). The data showed a 42% overall response rate and a median progression-free survival of 11.1 months in heavily pre-treated patients with ER+/HER2- breast cancer. Pending additional data, Arvinas and Pfizer plan to broaden development of vepdegestrant to include new combinations with CDK inhibitors in both the first- and second-line settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.86%
Tags
clinical trial
-
News
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
Rhea-AI Summary
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced updated clinical trial data for vepdegestrant (ARV-471) to be presented at the 2023 San Antonio Breast Cancer Symposium. Vepdegestrant is a potential treatment for patients with locally advanced or metastatic estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
News
Arvinas Announces Oversubscribed $350 Million Private Placement
Rhea-AI Summary
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), has announced a private placement to sell 12,963,542 shares of common stock and pre-funded warrants to purchase up to 3,422,380 shares, expecting to raise approximately $350 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.24%
Tags
none
-
News
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Arvinas, Inc. reported financial results for Q3 2023 and provided a corporate update. They continue enrollment in Phase 3 trials for vepdegestrant and presented mCRPC data at ESMO. They anticipate completion of the first Phase 3 trial with vepdegestrant in 2H 2024 and have a lot of milestones to deliver in 2024. Financially, they believe their cash position is sufficient to fund planned operating expenses and capital expenditure requirements into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
earnings
-
News
Arvinas to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Arvinas, Inc. (Nasdaq: ARVN) will participate in five upcoming investor conferences: Truist Securities BioPharma Symposium, Stifel Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and 6th Annual Evercore ISI HealthCONx Conference. Key executives and officers will be available for one-on-one meetings and will participate in fireside chats. Live audio webcasts will be available on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
News
Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC
Rhea-AI Summary
Arvinas announces interim data from Phase 1/2 trial of bavdegalutamide and ARV-766 in mCRPC patients with AR mutations
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Arvinas Gives Back to Local Greater New Haven Community in Second Annual Impact Day
Rhea-AI Summary
Arvinas, Inc. announces successful second annual 'Arvinas Impact Day' where employees participated in community service activities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.56%
Tags
none
-
News
Arvinas to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Arvinas, Inc. (Nasdaq: ARVN) to participate in three upcoming investor conferences: Wells Fargo 2023 Healthcare Conference, Morgan Stanley 21st Annual Global Healthcare Conference, and Cantor Global Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
conferences
News
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
earnings
Stock ARVN logo
Arvinas Inc

Nasdaq:ARVN

ARVN Rankings

#1811 Ranked by Market Cap
#5164 Ranked by Stock Gains
N/A Ranked by Dividends

ARVN Stock Data

2.28B
55.84M
2.56%
97.28%
12.63%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
New Haven

About ARVN

arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.